Thermo Fisher Scientific Inc.
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $44.56 billion, up 4% year-over-year (up 2% organic) |
| Net income attributable to Thermo Fisher (FY2025) | $6.70 billion, up 5.8% year-over-year from $6.34 billion in FY2024 |
| GAAP diluted EPS (FY2025) | $17.74 |
| Adjusted operating margin (FY2025) | 22.7% |
| Adjusted EPS, non-GAAP (FY2025) | $22.87, up from $21.86 in FY2024 |
| Free cash flow (FY2025) | $6.34 billion |
| Employees (as of December 31, 2025, secondary-sourced estimate) | approximately 125,000, roughly unchanged year-over-year |
Sources: Segment figures are from Thermo Fisher Scientific's Q4/FY2025 earnings release (SEC Form 8-K Exhibit 99.1, reported January 29, 2026). No specifically-attributed third-party market-share estimate for Thermo Fisher's life sciences tools/instruments business could be confidently sourced (market-research reports naming Thermo Fisher as a leading player were found, but without a disclosed numeric share), so none is included. The employee headcount figure is drawn from a secondary aggregator rather than a directly quoted 10-K sentence and should be treated as somewhat less certain than the other figures here.